US20080249065A1 - Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate - Google Patents

Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate Download PDF

Info

Publication number: US20080249065A1
Authority: US; United States
Prior art keywords: ophthalmic pharmaceutical; pharmaceutical composition; patient; proline; leucine
Prior art date: 2005-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US12/091,481

Other languages

English (en)

Inventor

Franco Conti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Professional Dietetics SpA

Original Assignee

SOLARTIUM LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2006-10-16

Publication date

2008-10-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37561156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080249065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-16 Application filed by SOLARTIUM LLC filed Critical SOLARTIUM LLC

2008-04-24 Assigned to SOLARTIUM LLC reassignment SOLARTIUM LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONTI, FRANCO

2008-10-09 Publication of US20080249065A1 publication Critical patent/US20080249065A1/en

2011-05-04 Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLARTIUM ENTERPRISED LIMITED

2011-06-24 Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 026223, FRAME 0844 Assignors: SOLARTIUM ENTERPRISES LIMITED

Status Abandoned legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
229920002385 Sodium hyaluronate Polymers 0.000 title claims abstract description 15
229940010747 sodium hyaluronate Drugs 0.000 title claims abstract description 15
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 title claims abstract description 15
150000001413 amino acids Chemical class 0.000 title abstract description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 24
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
229960003136 leucine Drugs 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 15
229960002429 proline Drugs 0.000 claims description 15
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
239000004471 Glycine Substances 0.000 claims description 11
235000019454 L-leucine Nutrition 0.000 claims description 11
239000004395 L-leucine Substances 0.000 claims description 11
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
229930182821 L-proline Natural products 0.000 claims description 11
239000000607 artificial tear Substances 0.000 claims description 11
239000003889 eye drop Substances 0.000 claims description 9
208000003556 Dry Eye Syndromes Diseases 0.000 claims description 8
206010013774 Dry eye Diseases 0.000 claims description 8
229940012356 eye drops Drugs 0.000 claims description 8
229960003646 lysine Drugs 0.000 claims description 8
239000004472 Lysine Substances 0.000 claims description 7
239000000499 gel Substances 0.000 claims description 7
239000002674 ointment Substances 0.000 claims description 7
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
230000001575 pathological effect Effects 0.000 claims description 5
230000000472 traumatic effect Effects 0.000 claims description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
229960002449 glycine Drugs 0.000 claims description 4
235000018977 lysine Nutrition 0.000 claims description 4
208000024891 symptom Diseases 0.000 claims description 4
235000019766 L-Lysine Nutrition 0.000 claims description 3
206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 2
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical group CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 2
230000029663 wound healing Effects 0.000 abstract description 2
238000001356 surgical procedure Methods 0.000 description 6
208000002177 Cataract Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000035876 healing Effects 0.000 description 4
210000000110 microvilli Anatomy 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002980 postoperative effect Effects 0.000 description 3
239000008213 purified water Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001172 regenerating effect Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
206010011026 Corneal lesion Diseases 0.000 description 2
229920002306 Glycocalyx Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
201000007717 corneal ulcer Diseases 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
210000003560 epithelium corneal Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
210000004517 glycocalyx Anatomy 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011282 treatment Methods 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000003583 cytomorphological effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000249 desinfective effect Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002430 laser surgery Methods 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000009519 pharmacological trial Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000003357 wound healing promoting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions

Definitions

the present invention relates to ophthalmic pharmaceutical compositions, based on amino acids and sodium hyaluronate, with a protective and regenerating action on the corneal epithelial cells.
Dry eye syndrome is treated with eyedrops or gels (artificial tears) having a cleansing, lubricant and disinfecting action, which possess the chemico-physical characteristics of natural tears.
treatment usually involves administering topical preparations (eyedrops, ointments or artificial tears) with an antibiotic and anti-inflammatory activity.
the invention therefore relates to ophthalmic pharmaceutical compositions containing, as active ingredient, a combination of:
compositions according to the invention contain glycine, L-proline and sodium hyaluronate, and possibly L-lysine in the form of hydrochloride and L-leucine.
compositions according to the invention have a surprising effect as adjuvants: they aid regeneration of the epithelial microvilli and induce and accelerate corneal re-epithelialisation after eye surgery.
compositions according to the invention will therefore be used to treat:
compositions according to the invention will be applied to the eye 4-6 times a day, for a maximum of 3 months.
compositions according to the invention will contain the various active ingredients within the following percentage ranges by weight:
compositions according to the invention will contain the various active ingredients in the following percentages by weight:
Sodium hyaluronate is added separately to 100 kg of purified water, and stirred until the component has completely dissolved.
the two solutions are combined and made up to the final volume of 144 litres with purified water, checking that the pH value is between 6 and 7, and adjusting with citric acid or sodium bicarbonate if necessary.
the solution is filtered through an 0.22 ⁇ m filter under sterile conditions and placed in a container.
the protective and regenerative efficacy of the artificial tears according to the invention in reconstituting the corneal epithelium and stromal tissue in the case of pathological, traumatic, surgical, or parasurgical corneal lesions was investigated.
Group B the post-operative re-epithelialisation time was shortened from the usual 4-6 days to 2-3 days, and the administration of artificial tears, even after re-epithelialisation was complete, proved to prevent the appearance of haze and the dry eye syndrome typical of the first few months after surgery.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

US12/091,481 2005-10-26 2006-10-16 Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate Abandoned US20080249065A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITMI2005A002036		2005-10-26
IT002036A ITMI20052036A1 (it)	2005-10-26	2005-10-26	Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
PCT/EP2006/009967 WO2007048523A1 (en)	2005-10-26	2006-10-16	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/EP2006/009967 A-371-Of-International WO2007048523A1 (en)	2005-10-26	2006-10-16	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US12/964,522 Continuation US8524687B2 (en)	2005-10-26	2010-12-09	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Publications (1)

Publication Number	Publication Date
US20080249065A1 true US20080249065A1 (en)	2008-10-09

Family

ID=37561156

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US12/091,481 Abandoned US20080249065A1 (en)	2005-10-26	2006-10-16	Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate
US12/964,522 Active 2026-11-02 US8524687B2 (en)	2005-10-26	2010-12-09	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US12/964,522 Active 2026-11-02 US8524687B2 (en)	2005-10-26	2010-12-09	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Country Status (11)

Country	Link
US (2)	US20080249065A1 (de)
EP (1)	EP1940381B1 (de)
JP (1)	JP5312946B2 (de)
KR (1)	KR20080074107A (de)
AT (1)	ATE451916T1 (de)
CA (1)	CA2627215C (de)
DE (1)	DE602006011196D1 (de)
ES (1)	ES2335437T3 (de)
IT (1)	ITMI20052036A1 (de)
PL (1)	PL1940381T3 (de)
WO (1)	WO2007048523A1 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) *	2005-10-26	2008-11-20	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
US20110287064A1 (en) *	2010-05-19	2011-11-24	Heraeus Medical Gmbh	Antibiotic coating
US20120316217A1 (en) *	2009-12-21	2012-12-13	Professional Dietetics S.R.L.	combination for the treatment of osteoarthritis
EP2504001B1 (de)	2009-11-26	2015-03-04	Professional Dietetics S.r.l.	Kombination zur behandlung von strahlungs- oder chemotherapiebedingter mukositis

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2540481C2 (ru) *	2009-07-27	2015-02-10	Сальваторе Троизи	Офтальмологический раствор для защиты внутренних структур глазного яблока от уф-а лучей или для лечения кератоконуса методом трансэпителиального кросс-линкинга
CN104758921A (zh) *	2010-11-08	2015-07-08	希尔洛有限公司	缓冲的眼用组合物以及使用其的方法
AT511164A1 (de)	2011-03-03	2012-09-15	Croma Pharma Gmbh	Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges
ITMI20110954A1 (it) *	2011-05-26	2012-11-27	Professional Dietetics Srl	Combinazioni per il trattamento delle mucositi vaginali o rettali
ES2604816B1 (es) *	2015-09-09	2018-01-29	Farmalider, S.A.	Composición farmacéutica de tramadol para uso oftálmico
IT201600116727A1 (it) *	2016-11-18	2018-05-18	Univ Politecnica Delle Marche	Composto per la guarigione di ferite
BR112021000724A2 (pt)	2018-07-27	2021-04-13	Johnson & Johnson Surgical Vision, Inc.	Composições e métodos para tratar os olhos
US10966948B2 (en)	2019-07-23	2021-04-06	Johnson & Johnson Surgical Vision, Inc.	Compositions and methods for treating the eye
US20200030226A1 (en)	2018-07-27	2020-01-30	Johnson & Johnson Consumer Inc.	Botanical and bacterial extracts displaying retinol-like activity
US11969454B2 (en)	2019-11-19	2024-04-30	Johnson & Johnson Surgical Vision, Inc.	Compositions and methods for treating the eye
WO2021170290A1 (en)	2020-02-28	2021-09-02	Immunologik Gmbh	Inhibitors of human deubiquitinases for the treatment of coronaviral infections
US20230165851A1 (en)	2020-04-27	2023-06-01	Immunologik Gmbh	6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
AU2021288757B2 (en)	2020-06-10	2026-01-08	Metriopharm Ag	Compound for the treatment of coronaviral infections
EP3981405A1 (de)	2020-10-08	2022-04-13	MetrioPharm AG	Verbindung zur behandlung von coronavirusinfektionen
WO2022042873A1 (en)	2020-08-27	2022-03-03	Immunologik Gmbh	Pharmaceutically acceptable lectins derived from plants, fungi and bacteria for the treatment of sars-cov-2 infections
IT202100029726A1 (it)	2021-11-24	2023-05-24	Professional Dietetics Spa	Composizioni oftalmiche per il trattamento di lesioni corneali
EP4193994A1 (de)	2021-12-08	2023-06-14	MetrioPharm AG	Kombination von 5-amino-2,3-dihydro-1,4-phtalazinedion und einem 6'-methoxycinchonan-9-ol zur verwendung bei der behandlung von coronaviralen infektionen
EP4784132A1 (de)	2023-09-26	2026-08-05	MetrioPharm AG	5-amino-2,3-dihydro-1,4-phthalazindione zur behandlung von infektionen mit einem rna-virus

Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707354A (en) *	1985-06-17	1987-11-17	Alpen Tau, Inc.	Mature skin treatment and protectant compositions and methods of using same
US5741817A (en) *	1994-07-22	1998-04-21	Chowhan; Masood	Use of low molecular weight amino acids in ophthalmic compositions
US20020013359A1 (en) *	2000-06-07	2002-01-31	Dioguardi Francesco Saverio	Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds
US20030021834A1 (en) *	1996-08-07	2003-01-30	Petito George D.	Method for use of hyaluronic acid in wound management
US20030091652A1 (en) *	2001-11-13	2003-05-15	Suhail Ishaq	Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US20040004744A1 (en) *	2002-07-02	2004-01-08	Peter Haider	Apparatus and method for obtaining image information from an image original
US20040006348A1 (en) *	1999-08-26	2004-01-08	The Spineology Group, Llc	Tools and method for processing and injecting bone graft material
US20040180025A1 (en) *	2003-03-12	2004-09-16	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040265268A1 (en) *	2001-08-18	2004-12-30	Deepak Jain	Compositions and methods for skin rejuvenation and repair
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) *	2005-10-26	2008-11-20	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6084225A (ja) *	1983-10-17	1985-05-13	Hiroko Shimizu	点眼剤
JPH0723317B2 (ja) *	1988-03-17	1995-03-15	生化学工業株式会社	角膜上皮層障害症治療剤
JP3050898B2 (ja) *	1990-07-06	2000-06-12	千寿製薬株式会社	水性医薬製剤
JPH10290830A (ja) *	1997-04-18	1998-11-04	Ofutekusu:Kk	眼手術用補助剤
US6645948B2 (en)	1998-03-24	2003-11-11	George D. Petito	Nutritional composition for the treatment of connective tissue
US6654948B1 (en) *	1999-10-12	2003-11-25	International Business Machines Corporation	Methods and apparatus for partial and consistent monitoring of object-oriented programs and systems
ITTO20010804A1 (it) *	2001-08-08	2003-02-08	Professional Dietetics Srl	Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
US20060094643A1 (en) *	2002-07-03	2006-05-04	Yuri Svirkin	Compositions of hyaluronic acid and methods of use
FR2849383B1 (fr) *	2002-12-26	2005-09-30	Jean Noel Thorel	Composition trophique en milieu aqueux, et ses applications, notamment en ophtalmologie
GB0404693D0 (en) *	2004-03-02	2004-04-07	Univ London	Pharmaceutical preparations for the treatment of ocular surface and other disorders

2005
- 2005-10-26 IT IT002036A patent/ITMI20052036A1/it unknown
2006
- 2006-10-16 JP JP2008536974A patent/JP5312946B2/ja not_active Expired - Fee Related
- 2006-10-16 CA CA2627215A patent/CA2627215C/en active Active
- 2006-10-16 KR KR1020087009861A patent/KR20080074107A/ko not_active Ceased
- 2006-10-16 EP EP06806304A patent/EP1940381B1/de active Active
- 2006-10-16 ES ES06806304T patent/ES2335437T3/es active Active
- 2006-10-16 AT AT06806304T patent/ATE451916T1/de not_active IP Right Cessation
- 2006-10-16 WO PCT/EP2006/009967 patent/WO2007048523A1/en not_active Ceased
- 2006-10-16 DE DE602006011196T patent/DE602006011196D1/de active Active
- 2006-10-16 US US12/091,481 patent/US20080249065A1/en not_active Abandoned
- 2006-10-16 PL PL06806304T patent/PL1940381T3/pl unknown
2010
- 2010-12-09 US US12/964,522 patent/US8524687B2/en active Active

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707354A (en) *	1985-06-17	1987-11-17	Alpen Tau, Inc.	Mature skin treatment and protectant compositions and methods of using same
US5741817A (en) *	1994-07-22	1998-04-21	Chowhan; Masood	Use of low molecular weight amino acids in ophthalmic compositions
US20030021834A1 (en) *	1996-08-07	2003-01-30	Petito George D.	Method for use of hyaluronic acid in wound management
US20040006348A1 (en) *	1999-08-26	2004-01-08	The Spineology Group, Llc	Tools and method for processing and injecting bone graft material
US20020013359A1 (en) *	2000-06-07	2002-01-31	Dioguardi Francesco Saverio	Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds
US20040265268A1 (en) *	2001-08-18	2004-12-30	Deepak Jain	Compositions and methods for skin rejuvenation and repair
US20030091652A1 (en) *	2001-11-13	2003-05-15	Suhail Ishaq	Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US20040004744A1 (en) *	2002-07-02	2004-01-08	Peter Haider	Apparatus and method for obtaining image information from an image original
US20040180025A1 (en) *	2003-03-12	2004-09-16	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) *	2005-10-26	2008-11-20	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080261915A1 (en) *	2005-10-26	2008-10-23	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) *	2005-10-26	2008-11-20	Solartium Llc	Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
EP2504001B1 (de)	2009-11-26	2015-03-04	Professional Dietetics S.r.l.	Kombination zur behandlung von strahlungs- oder chemotherapiebedingter mukositis
US20120316217A1 (en) *	2009-12-21	2012-12-13	Professional Dietetics S.R.L.	combination for the treatment of osteoarthritis
US20110287064A1 (en) *	2010-05-19	2011-11-24	Heraeus Medical Gmbh	Antibiotic coating

Also Published As

Publication number	Publication date
CA2627215A1 (en)	2007-05-03
ITMI20052036A1 (it)	2007-04-27
CA2627215C (en)	2015-03-24
US8524687B2 (en)	2013-09-03
JP5312946B2 (ja)	2013-10-09
JP2009513586A (ja)	2009-04-02
KR20080074107A (ko)	2008-08-12
EP1940381A1 (de)	2008-07-09
PL1940381T3 (pl)	2010-05-31
US20110077219A1 (en)	2011-03-31
WO2007048523A1 (en)	2007-05-03
ATE451916T1 (de)	2010-01-15
EP1940381B1 (de)	2009-12-16
DE602006011196D1 (de)	2010-01-28
ES2335437T3 (es)	2010-03-26

Legal Events

Date

Code

Title

Description

2008-04-24

AS

Assignment

Owner name: SOLARTIUM LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONTI, FRANCO;REEL/FRAME:020853/0679

Effective date: 20080317

2011-02-28

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

2011-05-04

AS

Assignment

Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLARTIUM ENTERPRISED LIMITED;REEL/FRAME:026223/0844

Effective date: 20110117

Publication	Publication Date	Title
US8524687B2 (en)	2013-09-03	Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate
US7871646B2 (en)	2011-01-18	Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
US5811446A (en)	1998-09-22	Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20220332773A1 (en)	2022-10-20	Silk-derived protein for treating inflammation
US6984628B2 (en)	2006-01-10	Ophthalmic compositions comprising trefoil factor family peptides
US20110275688A1 (en)	2011-11-10	Ketorolac compositions for corneal wound healing
MX2012005816A (es)	2012-06-19	Uso de prostaglandinas f2alfa y analogos para la curacion de lesiones de cornea y conjuntiva.
KR20050086937A (ko)	2005-08-30	안구 건조의 치료에 있어서 리멕솔론의 용도
US20250000790A1 (en)	2025-01-02	Ketorolac compositions for corneal wound healing
De Monchy et al.	2012	Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report
US8426384B2 (en)	2013-04-23	Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
Aldavood et al.	2003	Effect of acetylcysteine on experimental corneal wounds in dogs
TW443931B (en)	2001-07-01	A therapeutic agent for the treatment of disorders of corneal and conjuntival epithelia
WO1999038497A2 (en)	1999-08-05	Ophthalmic composition
JP2024528700A (ja)	2024-07-30	細胞喪失を治療又は阻害するためのヒスタチンの組み合わせ及び方法
RU2840756C1 (ru)	2025-05-28	Способ консервативного лечения нейротрофического кератита
KR20150067517A (ko)	2015-06-18	녹내장 여과수술 후 흉터 예방 또는 치료용 약학조성물
Mallias et al.	2017	Fungal keratitis after Descemet stripping automated endothelial keratoplasty
Gholipour et al.	2010	Effect of dexamethasone in combination with acetylcysteine at different times on corneal wound healing in dogs
JPWO1999043347A1 (ja)	2002-10-08	角膜上皮障害症治療剤

US20080249065A1 - Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate - Google Patents

Info

Links

Classifications

Definitions

Landscapes

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=37561156

Family Applications (2)

Family Applications After (1)

Country Status (11)

Cited By (5)

Families Citing this family (18)

Citations (11)

Family Cites Families (10)

Patent Citations (11)

Cited By (5)

Also Published As

Similar Documents

Legal Events